Invectys
PrivateLast Round
Early Funding
Oct 10, 2024
Total Funding Raised
$40.1M
Company Overview
Invectys is a biopharmaceutical company that develops innovative immunotherapy approaches to treat cancer by targeting HLA-G and telomerase antigens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Invectys Comparables
Compare Invectys with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AffyImmune Therapeutics | 83% | |
| NKILT Therapeutics | 80% | |
| Tizona Therapeutics | 79% | |
Invectys Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 10, 2024 | ||||
| Grant | May 20, 2020 | ||||
| Series A | Oct 29, 2018 | ||||
| Early Funding | Jul 1, 2017 |
Key People
Founding team and executive leadership
Invectys Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 10, 2024
$4M raised in early funding.
Invectys Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Invectys's valuation, stock price, and market status.